|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Bamias A et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23(34):8580-7. Abstract
Bekker PJ et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19(7):1059-66. Abstract
Berenson JR et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16(2):593-602. Abstract
Berenson JR et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334(8):488-93. Abstract
Coleman RE et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23(22):4925-35. Abstract
Diel IJ et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339(6):357-63. Abstract
Hoff AO et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. Proc ASCO 2006;Abstract 8528.
Hortobagyi GN et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16(6):2038-44. Abstract
Hortobagyi GN et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335(24):1785-91. Abstract
Lipton A et al. Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP). Proc ASCO 2006;Abstract 512.
Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program. Semin Oncol 2001;28(2 Suppl 6):17-24. Abstract
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61(9):1115-7. No abstract available
Powles T et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006;8(2):R13. Abstract
Rosen LS et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003;98(8):1735-44. Abstract
Rosen LS et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial — The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21(16):3150-7. Abstract
Ruggiero SL et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62(5):527-34. Abstract
Saad F et al; Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96(11):879-82. Abstract
Saarto T et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004;43(7):650-6. Abstract
Van Poznak CH et al. Osteonecrosis of the jaw in patients with metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 3057.
 |
 |
